Investor pressure pushing drugmakers to make deals

Back to TopCommentsE-mailPrintBookmark and Share

Drugmakers eager to satisfy shareholders by boosting profit and share prices are wheeling, dealing and in one case even making trades like a pro sports team looking to shake up its roster. The moves could spur more mergers and acquisitions in the industry.

Tuesday's blockbuster deal involving Indianapolis-based Eli Lilly and Co. was just the latest of several that have taken place since the beginning of the year.

In that deal, Swiss drugmaker Novartis AG said it's trading its vaccine business for GlaxoSmithKline Plc's cancer drug business and selling its veterinary drug business to Lilly.

Lilly shares were down 10 cents late Wednesday morning, to $59.92 each, one day after falling 94 cents in wake of the deal's announcement.

Meanwhile on Tuesday, Canadian drugmaker Valeant Pharmaceuticals International Inc. said it teamed up with activist investor Bill Ackman in a bid for Botox maker Allergan that could be worth about $45 billion.

Amid easier financing and low interest rates, four smaller drugmakers also announced bids of $3 billion or more to acquire competitors since January, according to data and research firm The Mergermarket Group. The biggest is a $23 billion bid by Forest Laboratories Inc. for Actavis Inc.

The deals partly reflect a push by the pharmaceutical industry to boost sales and cut costs as drugmakers look for ways to return to the growth investors have come to expect after the bullish last two decades, when they continually churned out new blockbusters, drugs with annual sales of more than a billion dollars.

Most drugmakers have since seen revenue flatline or even dip as a tidal wave of cheaper generic competition to former blockbuster pills over the past few years wiped out billions of dollars in annual revenue. Others see the wave coming — Novartis, for instance, is awaiting generic competition to its blockbuster blood-pressure drug Diovan — and are trying to lessen the impact.

At the same time, research to develop new medicines to replace lost income is ever more difficult and expensive. Mergers and acquisitions give them additional sources of revenue and new ways to cut costs and become more efficient while they wait for drugs in their research pipeline to win approval.

Most of the spurt of mergers and acquisitions are meant to narrow the drugmaker's focus, a strategy that's in vogue now, partly due to pressure from analysts and investors. The pharmaceutical industry tends to cycle back and forth every several years between periods where most companies are divesting to focus on their core areas, or diversifying by snapping up other types of drugs or related businesses.

"Wall Street has been rewarding more-focused companies" with higher share prices, said Les Funtleyder, a consulting partner at healthcare investing firm BlueCloud Healthcare. "You see one company doing something and others feel like they have to make a strategic response."

Eric Gordon, an analyst and professor at the University of Michigan's Ross School of Business, said the industry is rearranging, with companies reducing the number of diseases they're attacking and divesting noncore businesses to others stronger in those fields.

"A few years ago, it would have been the opposite. They were acquiring things so they wouldn't be so dependent on one area" or drug, Gordon said. Then "that doesn't do the magic that's expected of it, so we divest and get focused. In 2019, we'll probably be conglomerating again."

In the short run, analysts say the deals will boost drugmakers' share prices and guarantee yet another round of layoffs in the industry. The layoffs, plus other synergies as the new assets are integrated, should boost profit margins in the midterm.

Meanwhile, patients "waiting for a cure" won't see benefits soon, but might eventually, Gordon said. That's because rejiggered companies with strong scientific teams and commitment to a particular disease area could be less likely to scrap experimental drugs in that field when they run into some bumps during patient testing. On the other hand, the companies may decide to reduce the number of experimental drugs they push through increasingly expensive stages of patient testing.

"There is that danger," Gordon warned.


  • payed a premium
    The synergies that they will be saving from are lost jobs to Novartis Animal Products employees and Lilly Elanco employees. Sales duplication will be eliminated, and business functions such as accounting, finance, etc. duplications will be eliminated. Also, since most of the Novartis side is foreign based, Lilly can invest its foreign profits without any tax implications in the United States. A great deal for Lilly corporate, a less than great deal for Novartis Animal Product employees at headquarters offshore and Lilly Elanco sales offshore. The net is a combination funded by Lilly offshore dollars, no tax implications, and rank and file workers will take a hit, but not management in the executive ranks.

Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. Angela IS the best RD

  2. We are a nation of speed. All of our younger lives are filled with deadlines, quotas and bottom lines. We start to ease out of the pressured rat-race when we finally see "retirement." The most enjoyable travel on the planet is passenger rail service. Indy to Chicago does not beat Megabus or Southwest Airlines in speed. Passenger rail however has the best seating, mammoth legroon, seat backs that recline to more than 45 degrees and employers that really want you to return as a customer. Indiana municipalities need to maintain subsidies to support this transportation mode. Losing it is loss for all of us.

  3. Good day! I just want to testify how i got my loan from Mr. Eric Lefkofsky after i applied several times from various loan lenders who claimed to also testify right in this forum,i thought the testimonies where real and i applied but they never gave me loan. I was in need of an urgent loan to start a business and i applied from various loan lenders who promised to help but they never gave me the loan. Until a friend of mine introduce me to this popular Mr. Eric Lefkofsky who promised to help me and indeed he did as he promised without any form of delay. I never thought there are still reliable loan lenders until i met Mr. Eric lefkofsky who indeed helped me with the loan and changed my belief. I promised to share this testimony after I got my loan. I don't know if you are in any way in need of a genuine and urgent loan,free feel to contact Mr. Eric Lefkofsky via their email{grouponfunding@hotmail.com}

  4. Its a THUG issue. Bleecker Street and NYX are thug bars. They attract thugs of all races. Places that attract thugs need to be kicked out of Broad Ripple. Ain't nobody got time for that!

  5. Hello everyone, My name is Marian Gareth, I am from the Texas, United State, am here to testify of how i got my loan from Mr Andre Frank {frankloancompany@yahoo.com} after i applied Two times from various loan lenders who claimed to be lenders right in this forum,i thought their lending where real and i applied but they never gave me loan. I was in need of an urgent loan to start a business and i applied from various loan lenders who promised to help but they never gave me the loan.Until a friend of mine introduce me to Mr Andre Frank the C.E.O of Andre Frank Loan Company who promised to help me with a loan of my desire and he really did as he promised without any form of delay, I never thought there are still reliable loan lenders until i met Mr Andre Frank, who really help me with my loan and changed my lief for better. I don't know if you are in need of an urgent loan, free feel to contact Mr Andre Frank on his email{ Frankloancompany@yahoo.com} for help